Abstract
Aims: In this study, we aimed to determine mutations in the gene sequence of this virus, by performing whole genome sequence analysis from patient samples found positive by actual RT-PCR (PCR) for SARS-CoV-2.
 Methods: The study included six adult patient samples with different clinical manifestations with positive PCR tests for SARS-CoV-2, between June 01, 2020, and March 12, 2021. Sequence knowledge of all samples/testers has been loaded into the GISEAD (Global Initiative on Sharing All Influenza Data) data system. Clade Analysis, Genome Analysis, Variant Analysis, and Phylogenetic Tree Analysis were conducted.
 Results: 3 of the patients were women (female), and three were men(male), with the mean age of 42.5 years old (between 20 - 61). Totally 71 mutations were specified in 6 adult patients. By the Pangolin lineage, three of the patients were B.1.177, two were B.1, one was of B1.36 lineage. By the Pango lineage, two of the patients were B.1.609, one was B.177, one was B.1.36. By the Nexstrain Clade, four of the patients were 20A and two were of 19A lineage. No D614G mutation was detected in any of the patients. While five patients recovered, one patient with metastatic lung adenocarcinoma died.
 Conclusion; The patients were detected in the commonly found 'Non-VOC' group. Therefore, variants could not be associated with the clinical status and prognosis of the patients. However, it is thought that the data obtained contribute to both global and national SARS-CoV-2 data.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.